Ntensify™ systems
The Ntensify systems are at the heart of our RNA production technology. We designed our systems with end users’ needs in mind, creating a radically different manufacturing technology. With the Ntensify systems, we give you the tools to produce purified mRNA at the scale you need.
Mini
The Ntensify Mini is an R&D-grade RNA production system suitable for both drug discovery and pre-clinical development.
Drug discovery: the system can accommodate up to 192 different DNA templates in parallel for the In vitro transcription (IVT) of various RNA sequences at 0.5 µg of purified output per construct.
Midi
The Ntensify Midi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phases I and II.
In less than one day, the system can produce 1 to 5 g of purified RNA in Quantoom’s proprietary reactors using single-use consumables.
Modules are available to upgrade effortlessly from Ntensify Midi to Ntensify Maxi
Maxi
The Ntensify Maxi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phase III and commercial production.
The Ntensify Maxi is an upgrade of the Midi system to increase the scale. Only minor, easily implementable modifications are required.
The system can produce 33 g of purified RNA per day, in Quantoom’s proprietary reactors using single-use consumables.
Scalability is achieved through an innovative and patented sequential-continuous workflow.
Key facts
Pre-clinical: a single DNA template can be transcribed to produce over 100 mg of the same RNA which is pooled after purification.
-
In total, the equipment can produce up to 175,000 doses of purified RNA per year (50 µg each)
Key facts
-
Up to 5 g of purified RNA per day
-
More than 600 g of purified RNA per year
-
Up to 7.3 M doses of corresponding drug product (50 µg each)
Key facts
-
More than 40 batches a year
-
More than 8 kg of purified RNA per year
-
Up to 100 M doses of drug product per year (50 µg each)
Mini
The Ntensify Mini is an R&D-grade RNA production system suitable for both drug discovery and pre-clinical development.
Drug discovery: the system can accommodate up to 192 different DNA templates in parallel for the production of various RNA sequences at 0.5 µg of purified output per construct.
Key facts
-
Pre-clinical: a single DNA template can be transcribed to produce over 100 mg of the same RNA which is pooled after purification.
-
In total, the equipment can produce up to 175,000 doses of purified RNA per year (50 µg each)
Midi
The Ntensify Midi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phases I and II.
In less than one day, the system can produce 1 to 5 g of purified RNA in Quantoom’s proprietary reactors using single-use consumables.
Modules are available to upgrade effortlessly from Ntensify Midi to Ntensify Maxi
Key facts
-
Up to 5 g of purified RNA per day
-
More than 600 g of purified RNA per year
-
Up to 7.3 M doses of corresponding drug product (50 µg each)
Maxi
The Ntensify Maxi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phase III and commercial production.
The Ntensify Maxi is an upgrade of the Midi system to increase the scale. Only minor, easily implementable modifications are required.
The system can produce 33 g of purified RNA per day, in Quantoom’s proprietary reactors using single-use consumables.
Scalability is achieved through an innovative and patented sequential-continuous workflow.
Key facts
-
More than 40 batches a year
-
More than 8 kg of purified RNA per year
-
Up to 100 M doses of drug product per year (50 µg each)
Key features
-
No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
-
Single small footprint system that integrates all process steps – no need to invest in a suite of equipment
-
Generic process* that is adaptable to your specific RNA construct both for transcription and purification with polishing options
-
Reduced CoGs thanks to minimal labor & RNA expertise required
-
In vivo validated with multiple RNA constructs to de-risk your product development
-
Practical and flexible range of equipment to fit to all phases of a project, from drug discovery to commercial production
*We have developed an optimized in-vitro transcription method to obviate the need for downstream dsRNA clearance while improving reaction yield and reducing consumption of capping reagent without sacrificing capping yield. Our new process template has proven successful for different RNA constructs, requiring only minimal customization. Fewer purification steps are required while still guaranteeing high quality.
Key features:
No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
-
Single small footprint system that integrates all process steps – no need to invest in a suite of equipment
-
Generic process* that is adaptable to your specific RNA construct both for transcription and purification with polishing options
-
Reduced CoGs thanks to minimal labor & RNA expertise required
-
In vivo validated with multiple RNA constructs to de-risk your product development
-
Practical and flexible range of equipment to fit to all phases of a project, from drug discovery to commercial production
*We have developed an optimized in-vitro transcription method to obviate the need for downstream dsRNA clearance while improving reaction yield and reducing consumption of capping reagent without sacrificing capping yield. Our new process template has proven successful for different RNA constructs, requiring only minimal customization. Fewer purification steps are required while still guaranteeing high quality.
Contact Us
